MYC and lymphoma: For relative comparison, MYC does not rank in the top DEGs of this study, but the extent of downregulation (−17.108-fold change) is greater than the novel DEGs identified further strengthening the utility of selective CDK9 inhibitors for targeting MYC+ lymphomas.